Kevin Kemp

Summary

Affiliation: University of Bristol
Country: UK

Publications

  1. doi request reprint Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum
    Kevin Kemp
    Multiple Sclerosis and Stem Cell, School of Clinical Sciences, University of Bristol, Bristol, BS16 1JB, UK
    Brain 135:2962-72. 2012
  2. doi request reprint Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells
    K Kemp
    Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, UK
    Neuropathol Appl Neurobiol 37:166-78. 2011
  3. doi request reprint Mesenchymal stem cell-secreted superoxide dismutase promotes cerebellar neuronal survival
    Kevin Kemp
    Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, Clinical Sciences North Bristol, University of Bristol, Bristol, UK
    J Neurochem 114:1569-80. 2010
  4. doi request reprint Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy
    Kevin Kemp
    Center for Research in Biomedicine, Faculty of Applied Sciences, University of West of England, Bristol, UK
    Ann Hematol 89:701-13. 2010
  5. pmc Mesenchymal stem cells restore frataxin expression and increase hydrogen peroxide scavenging enzymes in Friedreich ataxia fibroblasts
    Kevin Kemp
    Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
    PLoS ONE 6:e26098. 2011
  6. doi request reprint Inflammatory cytokine induced regulation of superoxide dismutase 3 expression by human mesenchymal stem cells
    Kevin Kemp
    Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, Clinical Sciences North Bristol, University of Bristol, Bristol, UK
    Stem Cell Rev 6:548-59. 2010
  7. doi request reprint Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells
    Kevin Kemp
    Centre for Research in Biomedicine, Faculty of Applied Sciences, University of the West of England, Bristol, UK
    Ann Hematol 90:777-89. 2011
  8. doi request reprint Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases
    Claire M Rice
    University of Bristol Institute of Clinical Neurosciences, Burden MS Stem Cell Laboratories and BrAMS Unit, Frenchay Hospital, Bristol, UK
    Lancet 382:1204-13. 2013
  9. doi request reprint Changes in expression of the antioxidant enzyme SOD3 occur upon differentiation of human bone marrow-derived mesenchymal stem cells in vitro
    Helen Nightingale
    Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristo, Bristol, UK
    Stem Cells Dev 21:2026-35. 2012
  10. doi request reprint Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro
    Alastair Wilkins
    Department of Neurology, Institute of Clinical Neurosciences, Clinical Sciences North Bristol, University of Bristol, Bristol BS16 1LE, UK
    Stem Cell Res 3:63-70. 2009

Collaborators

Detail Information

Publications20

  1. doi request reprint Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum
    Kevin Kemp
    Multiple Sclerosis and Stem Cell, School of Clinical Sciences, University of Bristol, Bristol, BS16 1JB, UK
    Brain 135:2962-72. 2012
    ..It also suggests an exciting new avenue for therapeutic intervention, as enhancement or manipulation of fusion events may have a therapeutic role in cellular protection in multiple sclerosis...
  2. doi request reprint Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells
    K Kemp
    Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, UK
    Neuropathol Appl Neurobiol 37:166-78. 2011
    ..In addition, we examined whether tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma, factors associated with inflammation, increase cellular fusion between human MSCs and rodent cerebellar neurons in vitro...
  3. doi request reprint Mesenchymal stem cell-secreted superoxide dismutase promotes cerebellar neuronal survival
    Kevin Kemp
    Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, Clinical Sciences North Bristol, University of Bristol, Bristol, UK
    J Neurochem 114:1569-80. 2010
    ....
  4. doi request reprint Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy
    Kevin Kemp
    Center for Research in Biomedicine, Faculty of Applied Sciences, University of West of England, Bristol, UK
    Ann Hematol 89:701-13. 2010
    ....
  5. pmc Mesenchymal stem cells restore frataxin expression and increase hydrogen peroxide scavenging enzymes in Friedreich ataxia fibroblasts
    Kevin Kemp
    Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
    PLoS ONE 6:e26098. 2011
    ..These findings suggest, for the first time, that stem cells may increase frataxin levels in FRDA and transplantation of MSCs may offer an effective treatment for these patients...
  6. doi request reprint Inflammatory cytokine induced regulation of superoxide dismutase 3 expression by human mesenchymal stem cells
    Kevin Kemp
    Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, Clinical Sciences North Bristol, University of Bristol, Bristol, UK
    Stem Cell Rev 6:548-59. 2010
    ..SOD3 secretion by MSCs maybe of relevance to treatment strategies for inflammatory disease of the central nervous system...
  7. doi request reprint Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells
    Kevin Kemp
    Centre for Research in Biomedicine, Faculty of Applied Sciences, University of the West of England, Bristol, UK
    Ann Hematol 90:777-89. 2011
    ....
  8. doi request reprint Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases
    Claire M Rice
    University of Bristol Institute of Clinical Neurosciences, Burden MS Stem Cell Laboratories and BrAMS Unit, Frenchay Hospital, Bristol, UK
    Lancet 382:1204-13. 2013
    ..Additionally, these advances suggest avenues for translation of this approach not only for multiple sclerosis, but also for other common neurological and neurodegenerative diseases...
  9. doi request reprint Changes in expression of the antioxidant enzyme SOD3 occur upon differentiation of human bone marrow-derived mesenchymal stem cells in vitro
    Helen Nightingale
    Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristo, Bristol, UK
    Stem Cells Dev 21:2026-35. 2012
    ..This should help guide further in vivo work establishing the therapeutic and antioxidative potential of MSC and their differentiated progeny...
  10. doi request reprint Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro
    Alastair Wilkins
    Department of Neurology, Institute of Clinical Neurosciences, Clinical Sciences North Bristol, University of Bristol, Bristol BS16 1LE, UK
    Stem Cell Res 3:63-70. 2009
    ..These observations determine the mechanisms of neuroprotection offered by MSC-derived factors and suggest an important role for BDNF in neuronal protection...
  11. doi request reprint Human mesenchymal stem cells increase anti-oxidant defences in cells derived from patients with Friedreich's ataxia
    Rimi Dey
    Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristol, Bristol, UK
    Cerebellum 11:861-71. 2012
    ..This study further suggests the potential therapeutic use of MSCs in patients with FRDA...
  12. doi request reprint Peroxisome proliferator-activated receptor-α agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function
    Elizabeth Gray
    University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol BS16 1JB, UK
    Eur J Neurosci 33:1421-32. 2011
    ....
  13. doi request reprint Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis
    Elizabeth Mallam
    The MS Labs, The Burden Centre, Frenchay Hospital, Bristol, UK
    Mult Scler 16:909-18. 2010
    ....
  14. doi request reprint Neurofilament dot blot assays: novel means of assessing axon viability in culture
    Kelly Hares
    Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, Clinical Sciences, University of Bristol, North Bristol, UK
    J Neurosci Methods 198:195-203. 2011
    ....
  15. ncbi request reprint Reductions in neuronal peroxisomes in multiple sclerosis grey matter
    Elizabeth Gray
    MS and Stem Cell Labs, University of Bristol, UK
    Mult Scler 20:651-9. 2014
    ..Recent evidence has implicated peroxisomal dysfunction in models of multiple sclerosis (MS) disease progression...
  16. ncbi request reprint Increased microglial catalase activity in multiple sclerosis grey matter
    Elizabeth Gray
    MS Labs, Burden Centre, University of Bristol, Institute of Clinical Neurosciences, Frenchay Hospital, BS16 1JB Bristol, UK
    Brain Res 1559:55-64. 2014
    ..Collectively, these observations provide evidence that microglial catalase activity is elevated in MS grey matter and may be an important endogenous anti-oxidant defence mechanism in MS. ..
  17. pmc The PPAR-γ agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function
    Elizabeth Gray
    Multiple Sclerosis and Stem Cell Group, Burden Centre, Institute of Clinical Neurosciences, Frenchay Hospital, University of Bristol, Bristol BS16 1JB, UK
    J Neuroinflammation 9:63. 2012
    ..Recent evidence has suggested that oligodendrocyte peroxisomes may play an important role in protecting neurons from inflammatory damage...
  18. doi request reprint Human bone marrow mesenchymal stem cells protect catecholaminergic and serotonergic neuronal perikarya and transporter function from oxidative stress by the secretion of glial-derived neurotrophic factor
    Alan L Whone
    Department of Neurology, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristol, BS161LE, UK
    Brain Res 1431:86-96. 2012
    ..Trophic factor release may afford a way by which intravenously infused MSCs can offer protection to all of the dopaminergic, noradrenergic and serotonergic fibre types degenerating widely throughout the brains of patients with PD...
  19. pmc Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment
    Jonathan Witherick
    Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristol, Bristol BS16 1LE, UK
    Autoimmune Dis 2011:164608. 2010
    ..In this paper we focus on the antioxidant properties of mesenchymal stem cells and discuss their potential importance as a cell-based therapy for multiple sclerosis...
  20. doi request reprint Stem cells in genetic myelin disorders
    Kevin Kemp
    MS and Stem Cell Laboratories, Burden Centre, Frenchay Hospital, Bristol, UK
    Regen Med 5:425-39. 2010
    ..Specific stem cell subtypes and their relevance to potential therapeutic use will be discussed and stem cell transplantation in animal model studies will also be reviewed...